SynthesisAesthetic plastic surgery2026
Hyperbaric Oxygen Therapy for Ischemic Complications After Immediate Breast Reconstruction: A Systematic Review and Meta-Analysis.
Synthesis in Aesthetic plastic surgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundHyperbaric oxygen therapy (HBOT) has been proposed as an adjunct to enhance perfusion and support salvage of compromised breast reconstructions, but its role in the early postoperative phase remains insufficiently defined. This systematic review and meta-analysis evaluated the effectiveness and safety of HBOT during the early postoperative phase of first-stage breast reconstruction.
methodsA PRISMA-compliant search of PubMed, EMBASE, Cochrane CENTRAL, Web of Science, ScienceDirect, Scopus, Google Scholar, and ClinicalTrials.gov was conducted from inception to October 2025. Eligible studies included adults undergoing immediate or first-stage breast reconstruction who received HBOT for postoperative ischemia or necrosis and reported at least one clinical outcome. Methodological quality was assessed using MINORS for the comparative cohort study and the Murad et al. framework for case series, and overall certainty was evaluated using GRADE. Single-arm random-effects meta-analyses were performed for major clinical endpoints.
resultsFive observational studies (four case series and one retrospective cohort) comprising 409 patients met inclusion criteria, of whom 75 received HBOT. Therapy was typically initiated within the first 10 postoperative days and consisted of 10-20 sessions at 2.0-2.5 ATA. Pooled single-arm estimates demonstrated flap salvage of 82% (95% CI 72-90%) and pocket salvage of 78% (95% CI 65-88%). Reoperation and explantation rates were 15% (95% CI 9-23%) and 8% (95% CI 4-15%), respectively. Postoperative infections occurred in 3% (95% CI 1-7%). Adverse events were mild and infrequent.
conclusionsAlthough limited by small, predominantly observational studies and low certainty of evidence, current data suggest that HBOT may be a safe and potentially useful adjunct for managing ischemic complications after immediate breast reconstruction. Further well-designed prospective and randomized trials are required to define its optimal role. LEVEL OF EVIDENCE IV: This journal requires that authors assign a level of evidence to each article. For a full description of these Evidence-Based Medicine ratings, please refer to the Table of Contents or the online Instructions to Authors www.springer.com/00266 .
Indexed as
Identifiers
42270974What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.